Type III interferons (IFNs) are a family of recently identified antiviral cytokines. One to 3 paralogs have been identified in several species; however, little information is available about type III IFNs in pigs. We have identified 2 porcine type III IFNs, Sus scrofa IFN-λ1 (SsIFN-λ1) and SsIFN-λ3, and determined their tissue expression profile and antiviral activities. Open reading frames of SsIFN-λ1 and SsIFN-λ3 are 576 and 588 bp, encoding 191 and 195 amino acid preproteins, respectively. In healthy pigs, SsIFN-λ3 was primarily expressed in mesenteric lymph nodes and intestine, whereas expression of SsIFN-λ1 was found in all tested tissues and was high in mesenteric lymph nodes, intestine, and liver. Porcine cells treated with the viral mimic, dsRNA, robustly increased SsIFN-λ3 expression, with epithelial cells generally displaying the greatest response. Conversely, dsRNA-induced mRNA expressions of SsIFN-λ1, SsIFN-α1, and SsIFN-β were relatively weaker and delayed compared with SsIFN-λ3. SsIFN-λ1 and SsIFN-λ3 peptides exerted similar but lower antiviral potency than SsIFN-α1 and SsIFN-β against a porcine arterivirus and an adenovirus. These findings indicate that pigs have 2 type III IFN paralogs, which have antiviral activity and may serve as targets for modulation of the porcine host–pathogen interaction.
Get full access to this article
View all access options for this article.
References
1.
AnkN, IversenMB, BartholdyC, StaeheliP, HartmannR, JensenUB, Dagnaes-HansenF, ThomsenAR, ChenZ, HaugenH, KlucherK, PaludanSR. 2008. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol, 180:2474–2485.
2.
AnkN, PaludanSR. 2009. Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors, 35:82–87.
BordenEC, SenGC, UzeG, SilvermanRH, RansohoffRM, FosterGR, StarkGR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov, 6:975–990.
5.
DumoutierL, TounsiA, MichielsT, SommereynsC, KotenkoSV, RenauldJC. 2004. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem, 279:32269–32274.
6.
FoxBA, SheppardPO, O'HaraPJ. 2009. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PLoS ONE, 4:e4933.
7.
GadHH, DellgrenC, HammingOJ, VendsS, PaludanSR, HartmannR. 2009. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem, 284:20869–20875.
8.
HagedornTM, CarlinRW, SchultzBD. 2007. Oxytocin and vasopressin stimulate anion secretion by human and porcine vas deferens epithelia. Biol Reprod, 77:416–424.
9.
HallTA. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser, 41:95–98.
10.
KolodziejPA, YoungRA. 1991. Epitope tagging and protein surveillance. Methods Enzymol, 194:508–519.
11.
KotenkoSV, GallagherG, BaurinVV, Lewis-AntesA, ShenM, ShahNK, LangerJA, SheikhF, DickensheetsH, DonnellyRP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol, 4:69–77.
12.
KozakM. 1987. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res, 15:8125–8148.
MahdiRN, RouchkaEC. 2009. RBF-TSS: identification of transcription start site in human using radial basis functions network and oligonucleotide positional frequencies. PLoS ONE, 4:e4878.
15.
MeagerA, VisvalingamK, DilgerP, BryanD, WadhwaM. 2005. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine, 31:109–118.
16.
OhlerU, NiemannH. 2001. Identification and analysis of eukaryotic promoters: recent computational approaches. Trends Genet, 17:56–60.
17.
OnoguchiK, YoneyamaM, TakemuraA, AkiraS, TaniguchiT, NamikiH, FujitaT. 2007. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem, 282:7576–7581.
18.
OsterlundPI, PietiläTE, VeckmanV, KotenkoSV, JulkunenI. 2007. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol, 179:3434–3442.
19.
PestkaS. 2007. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem, 282:20047–20051.
20.
RostB, YachdavG, LiuJ. 2004. The PredictProtein server. Nucleic Acids Res, 32,Web Server issue:W321–W326.
21.
SangY, PatilAA, ZhangG, RossCR, BlechaF. 2006. Bioinformatic and expression analysis of novel porcine β-defensins. Mamm Genome, 17:332–339.
22.
SangY, RamanathanB, RossCR, BlechaF. 2005. Gene silencing and overexpression of porcine peptidoglycan recognition protein long isoforms: involvement in beta-defensin-1 expression. Infect Immun, 73:7133–7141.
SheppardP, KindsvogelW, XuW, HendersonK, SchlutsmeyerS, WhitmoreTE, KuestnerR, GarriguesU, BirksC, RorabackJ, OstranderC, DongD, ShinJ, PresnellS, FoxB, HaldemanB, CooperE, TaftD, GilbertT, GrantFJ, TackettM, KrivanW, McKnightG, CleggC, FosterD, KlucherKM. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol, 4:63–68.
25.
SommereynsC, PaulS, StaeheliP, MichielsT. 2008. IFN-lambda is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog, 4:e1000017.
WangJ, Oberley-DeeganR, WangS, NikradM, FunkCJ, HartshornKL, MasonRJ. 2009. Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda1) in response to influenza A infection. J Immunol, 182:1296–1304.
28.
YehRF, LimLP, BurgeCB. 2001. Computational inference of homologous gene structures in the human genome. Genome Res, 11:803–816.
29.
ZhangSY, Boisson-DupuisS, ChapgierA, YangK, BustamanteJ, PuelA, PicardC, AbelL, JouanguyE, CasanovaJL. 2008. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev, 226:29–40.
30.
ZhouL, WangX, WangYJ, ZhouY, HuS, YeL, HouW, LiH, HoWZ. 2009. Activation of toll-like receptor-3 induces interferon-lambda expression in human neuronal cells. Neuroscience, 159:629–637.
